Fresenius Medical Care has signed a global partnership agreement to commercialise Humacyte’s investigational human acellular vessel Humacyl.

Fresenius Medical Care will be responsible for its marketing and distribution following the approval by health authorities.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The transaction will be closed in July, subject to customary closing conditions and other regulatory approvals.

Based in Germany, Fresenius Medical Care is a supplier of renal dialysis products, while Humacyte is a US-based medical research and development company focused on novel technologies.

The partnership will enable Humacyte to advance the development of Humacyl and continue the development of its future pipeline products.

Senseonics has entered an agreement to integrate its Eversense Continuous Glucose Monitoring (CGM) system with Beta Bionics’s bionic pancreas system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The partnership will enable Humacyte to advance the development of Humacyl and continue the development of its future pipeline products.”

Based in the US, Senseonics focuses on the development of glucose monitoring products, while Beta Bionics, also based in the US, is a developer of bionic pancreas system iLet.

Sonion and Valencell have partnered to expand the use of biometric sensors for hearing instruments in the health, medical and consumer device markets.

Valencell will provide biometric sensor modules for hearables and wearables, which Sonion will optimise for size and cost for in-ear and on-ear applications, as part of the collaboration.

Valencell has also secured an undisclosed investment from Sonion through the strategic partnership.

Based in the US, Valencell is a manufacturer of wearable biometric sensor systems, while Sonion, also based in the US, is a manufacturer of micro-acoustic components for hearing aids.

The partnership will enable Valencell to strengthen its position in the hearables and hearing health markets.